NVN Liquidation Inc (Novan), formerly Novan Inc, is a clinical-stage biotechnology company that focuses on leveraging nitric oxide’s immunomodulatory and anti-microbial mechanisms of action for the treatment of various skin diseases. The company’s products find application in the treatment of dermatology disorders, gastroenterology and women’s health. Its pipeline products focus on treating acne vulgaris, external genital warts, onychomycosis, psoriasis, molluscum, tinea pedis, human papillomavirus (HPV) and atopic dermatitis. Novan uses its proprietary technology Nitricil to develop new chemical entities with sustained delivery of nitric oxide. It works in collaboration with academic institutions, universities, private and public companies. Novan is headquartered in Durham, North Carolina, the US.